#Biomarkers Market Share

[mordorintelligencemarketresearch]

The Biomarkers Industry: Transforming Healthcare with Precision Medicine

Biomarkers have emerged as a transformative force in the healthcare and biotechnology sectors, underpinning the shift toward precision medicine. These biological indicators, derived from measurable characteristics such as genes, proteins, or metabolites, provide critical insights into the health, disease progression, and therapeutic responses of individuals. The biomarkers industry is flourishing as advancements in medical science, diagnostics, and drug development continue to expand their utility across diverse clinical and research domains. 

The biomarkers market is projected to be valued at USD 56.72 billion in 2024 and is anticipated to grow to USD 87.64 billion by 2029, registering a compound annual growth rate (CAGR) of 9.09% during the forecast period from 2024 to 2029. 

Understanding Biomarkers and Their Importance 

Biomarkers, or biological markers, are measurable indicators of biological processes, pathogenic conditions, or pharmacologic responses to therapeutic interventions. They are categorized into three primary types: 

Diagnostic Biomarkers: Used to detect or confirm the presence of a disease or condition. 

Prognostic Biomarkers: Indicate the likely course or outcome of a disease. 

Predictive Biomarkers: Help forecast an individual's response to a specific treatment. 

These indicators play a critical role in early disease detection, personalized treatment planning, and monitoring therapeutic efficacy. The rising focus on precision medicine and targeted therapies has elevated the significance of biomarkers across healthcare disciplines. 

Key Drivers of Growth in the Biomarkers Industry 

1. Rising Prevalence of Chronic Diseases 

The global burden of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, has driven the demand for effective diagnostic and therapeutic tools. Biomarkers enable early disease detection and personalized treatment approaches, addressing the growing need for efficient healthcare solutions. 

2. Advancements in Genomics and Proteomics 

The integration of genomics, proteomics, and metabolomics into healthcare has accelerated biomarker discovery and application. High-throughput technologies, such as next-generation sequencing (NGS) and mass spectrometry, have expanded the understanding of disease mechanisms, paving the way for novel biomarkers. 

3. Expansion of Precision Medicine 

Precision medicine aims to tailor medical treatments to individual characteristics, leveraging biomarkers to guide therapeutic decisions. This approach has gained traction across oncology, neurology, and infectious diseases, driving the adoption of biomarkers in clinical practice. 

4. Growth of Companion Diagnostics 

Companion diagnostics, which rely on biomarkers to identify patients likely to benefit from specific therapies, have become integral to drug development. Regulatory agencies encourage the co-development of biomarkers and therapies, further boosting the biomarker industry. 

5. Increasing Investments in Research and Development 

Pharmaceutical and biotechnology companies, along with academic institutions, are investing heavily in biomarker research to accelerate drug discovery, improve clinical trials, and develop innovative diagnostics. Government initiatives and private funding have also supported biomarker research, fostering industry growth. 

Applications of Biomarkers 

1. Drug Discovery and Development 

Biomarkers have revolutionized drug development by enabling targeted therapies, improving clinical trial design, and reducing attrition rates. They help identify patient populations likely to respond to treatment, facilitating efficient trials and accelerating regulatory approval. 

2. Disease Diagnosis and Monitoring 

In diagnostics, biomarkers improve accuracy and enable early detection of diseases. For instance, cancer biomarkers such as HER2 and PSA (prostate-specific antigen) are widely used for diagnosis and monitoring disease progression. 

3. Personalized Medicine 

By providing insights into an individual’s genetic makeup, biomarkers guide the selection of tailored therapies, enhancing treatment outcomes and minimizing adverse effects. In oncology, for example, biomarkers like EGFR and ALK help determine the suitability of targeted therapies. 

4. Predictive and Prognostic Tools 

Biomarkers predict disease risk or therapeutic outcomes, allowing for proactive interventions. Prognostic biomarkers, such as BRAF mutations in melanoma, provide valuable information about disease progression. 

5. Infectious Disease Management 

Biomarkers play a critical role in managing infectious diseases by identifying pathogen-specific markers and evaluating treatment efficacy. During the COVID-19 pandemic, biomarkers like D-dimer and CRP were used to assess disease severity and guide patient management. 

Challenges in the Biomarkers Industry 

1. Validation and Standardization 

Ensuring the accuracy, reproducibility, and clinical relevance of biomarkers remains a challenge. Rigorous validation processes and standardized protocols are essential for integrating biomarkers into clinical practice. 

2. High Development Costs 

The discovery and validation of biomarkers involve extensive research, advanced technologies, and regulatory compliance, making the process costly and time-consuming. 

3. Regulatory Hurdles 

Biomarkers must meet stringent regulatory requirements for clinical use, which can delay their approval and commercialization. Harmonizing global regulatory frameworks is critical to overcoming this challenge. 

4. Limited Accessibility in Emerging Markets 

Despite advancements, the adoption of biomarkers in emerging markets is limited due to inadequate healthcare infrastructure, lack of awareness, and high costs. Bridging this gap is vital to ensure equitable access to biomarker-based diagnostics and treatments. 

5. Ethical and Privacy Concerns 

The use of biomarkers in genomics and personalized medicine raises ethical and privacy concerns, particularly regarding data security and informed consent. Addressing these issues is crucial to building trust and ensuring responsible use. 

Emerging Trends in the Biomarkers Industry 

1. Integration of Artificial Intelligence and Machine Learning 

AI and machine learning are transforming biomarker discovery by analyzing vast datasets to identify novel biomarkers. These technologies enhance pattern recognition, accelerate research, and improve diagnostic accuracy. 

2. Liquid Biopsy Advancements 

Liquid biopsies, which detect biomarkers in blood or other bodily fluids, are gaining momentum as a non-invasive diagnostic tool. They offer real-time monitoring of disease progression and treatment response, particularly in oncology. 

3. Multi-Omics Approaches 

Combining genomics, proteomics, transcriptomics, and metabolomics provides a comprehensive understanding of disease biology, facilitating the discovery of robust biomarkers. 

4. Digital Biomarkers 

The rise of wearable devices and mobile health applications has introduced digital biomarkers, which collect real-time data on physiological and behavioral parameters, enhancing patient monitoring and disease management. 

5. Collaboration and Open Data Sharing 

Collaborative efforts between academia, industry, and regulatory bodies are fostering innovation in biomarker research. Open data-sharing initiatives are accelerating the discovery of biomarkers and promoting transparency. 

Conclusion 

The biomarkers industry is at the forefront of transforming healthcare, enabling early diagnosis, personalized treatment, and efficient drug development. As advancements in technology and research continue to expand the scope of biomarkers, their impact on improving patient outcomes and healthcare efficiency is undeniable. 

While challenges such as validation, costs, and regulatory complexities persist, emerging trends like AI integration, liquid biopsies, and multi-omics approaches offer promising solutions. The biomarkers industry will play a pivotal role in shaping the future of precision medicine, addressing unmet medical needs, and revolutionizing patient care on a global scale.    For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/biomarkers-market 

[jesse-pinkman123]

The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the Biomarkers market dynamics.

[mrfrblogresearch02]

Biomarkers Market Strategy, Outlook and Product Development and COVID-19 Impact Analysis 2027

Market Overview: Biomarkers are defined as biological measures of a biological state. It is an indicator of normal biological processes, pharmacological responses or pathogenic processes for therapeutic intervention.

The global biomarkers market Size, during the forecast period 2019 to 2027, will register growth at a CAGR of 10.28%. The market for biomarkers is set to reach US$4,582.8 million income by 2027.

Biomarkers are clinical measures for assessment such as blood pressure or cholesterol level and help in monitoring and predicting health status in individuals as well as in populations which promotes planning of appropriate therapeutic intervention. Biomarkers are used to predict serious illnesses such as diabetes and cardiovascular disease. Each individual biomarker indicates whether there is a disease or health state and can be combined to provide a detailed picture of how healthy a person is and whether or not a diagnosis needs to be made. Biomarkers have proved to be especially helpful in cancer research as certain DNA or RNA markers may therefore help in the detection and treatment of specific cancers.

Market Segmentation: The biomarkers market size has been segmented into disease indication, application, type, and product. Based on the segment, which is disease indications, the market is categorized on the basis of cancer, cardiovascular disorders, immunological disorders, neurological disorders, and others. The global market for biomarkers is further segmented based on application into diagnostics, disease risk assessment, drug discovery and development, and personalized medicine. Furthermore, the market, on the basis of type, is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. Based on the segment, which is product, the market is categorized on the basis of consumables, services, and software. The global market research report covers all the aspects of the market based on the segmental analysis of these disease indications, application, type, and product segments. Analysts have also studied the global market's regional markets spread across many continents and countries. The disease indication, application, type, and product segments along with their sub-segments have been analyzed and companies functioning in the market across these segments are profiled and analyzed based on input and feedback from market-based decision makers as well as primary and secondary sources. The biomarkers market research report presents analysis-based information for companies functioning in the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1941 Regional Overview:

The spike in cancer cases globally may hinder the market growth. The market research report suggests that companies in the market could be supported by the spike in cancer cases globally as well as increasing applications and advancements of biomarkers during the forecast period. The market is set to register growth at a high CAGR owing to these key factors. The biomarkers market is spread across North America, Europe, Asia-Pacific, and other parts of the world. The global market research report reveals that APAC, North America, and Europe regional markets will dominate the global market for biomarkers during the forecast period 2019 to 2027. As per market analysts, the market is set to witness tremendous growth across consumables and safety biomarkers segments in North America which covers markets across the United States, Canada, Mexico and several other regional markets. Companies active in the market are also analyzed and studied in the market research report. The market for Europe covers smaller market segments of Germany, Italy, France, and the United Kingdom. Additionally, the market research report covers the Asia-Pacific region covering markets from India, China, Japan, Australia, and others. The biomarkers market is also spread across the rest of the world. The market report covers all such regions including the Middle East, Africa, Brazil, and others.

Competitive Landscape:

Qiagen N.V.,

Thermo Fisher Scientific Inc.,

Hoffmann-La Roche Ltd,

PerkinElmer Inc.,

Merck KGaA,

Bio-Rad Laboratories,

Abbott Laboratories,

EKF Diagnostics,

Enzo Biochem Inc.,

Meso Scale Diagnostics, LLC,

Signosis

PerkinElmer Inc.

Industry News: Medidata, a life science technology and clinical trial data firm, reported today that it has acquired the automated biomarker business of sensor manufacturer MC10. The deal's terms were kept under wraps. The acquisition would enable Medidata (a subsidiary of Dassault Systems) to incorporate biometric data and new analytics tools to its Patient Cloud platform, which will support patient-reported results, clinical outcome evaluations, and novel biomarker discovery, according to the company. Meanwhile, large corporations such as Johnson & Johnson and LabCorp have made significant efforts within their divisions to make remote clinical trial designs more feasible.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/biomarker-market-1941

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[futureresearchreportstrends]

Biomarkers Market is poised to value over USD 77.2 billion by 2027 end at a CAGR of over 13.5% during the forecast period 2020 to 2027

Growing usage of biomarkers in diagnostic applications, increased research and development funding for biotech and pharma companies, low costs of clinical trials in developing and underdeveloped countries and rapid prevalence of cancer across the world are some key driving factors that contribute in the growth of the market. FutureWise Market Research has instantiated a report that provides an intricate analysis of Biomarkers Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

[precedenceresearch]

Biomarkers Market Surpass US$ 137.7 Bn by 2027

Precedence Research states that the global biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 14.1 percent in the forecast period 2020 to 2027. The market is anticipated to be worth US$ 137.7 billion by 2027. The report provides an analysis of the global biomarkers market for the period 2016−2027, wherein 2020 to 2027 is the forecast period and 2020 is considered as…

[researchtrendingnews]

The Europe Biomarker Market is expected to reach USD 21,478.87 million by 2024, from USD 6,910.58 million in 2016 growing at a CAGR of 15.3% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

[jesse-pinkman123]

The report examines the Biomarkers market with respect to the industry trends, growth rate, prospects, drivers, restraints, threats, and lucrative opportunities, by means of distinguishing the high-growth segments of the market through the various stakeholders.

[mrfrblogresearch02]

Biomarkers Market to Deliver Greater Revenues during the Forecast Period till 2027

Market Overview: The global biomarkers market Size, during the forecast period 2019 to 2027, will register growth at a CAGR of 10.28%. The market for biomarkers is set to reach US$4,582.8 million income by 2027.

As per market analysts, the global market is anticipated to witness growth owing to the factors such as the escalating rate of chronic and life-threatening illnesses as well as an upsurge in the number of suppliers. However, the biomarkers market size will face challenges and restraints due to high capital investment and the increased level of investment required during the forecast period 2019 to 2027.

High prevalence of cancer in the market is set to play a key role in determining the growth potential during 2019 to 2027 years. Analysts have also studied the market to understand potential threats and challenges the market companies could face. Although the Biomarkers Market Size is poised to grow at a fast pace across disease indication, application, type, and product segments, factors such as increasing applications and advancements of biomarkers could slow down the market's growth worldwide.

Market Segmentation:

The biomarkers market size has been segmented into disease indication, application, type, and product. Based on the segment, which is disease indications, the market is categorized on the basis of cancer, cardiovascular disorders, immunological disorders, neurological disorders, and others. The global market for biomarkers is further segmented based on application into diagnostics, disease risk assessment, drug discovery and development, and personalized medicine. Furthermore, the market, on the basis of type, is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. Based on the segment, which is product, the market is categorized on the basis of consumables, services, and software.

The global market research report covers all the aspects of the market based on the segmental analysis of these disease indications, application, type, and product segments. Analysts have also studied the global market's regional markets spread across many continents and countries. The disease indication, application, type, and product segments along with their sub-segments have been analyzed and companies functioning in the market across these segments are profiled and analyzed based on input and feedback from market-based decision makers as well as primary and secondary sources. The biomarkers market research report presents analysis-based information for companies functioning in the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1941

Regional Overview:

The spike in cancer cases globally may hinder the market growth. The market research report suggests that companies in the market could be supported by the spike in cancer cases globally as well as increasing applications and advancements of biomarkers during the forecast period. The market is set to register growth at a high CAGR owing to these key factors. The biomarkers market is spread across North America, Europe, Asia-Pacific, and other parts of the world. The global market research report reveals that APAC, North America, and Europe regional markets will dominate the global market for biomarkers during the forecast period 2019 to 2027. As per market analysts, the market is set to witness tremendous growth across consumables and safety biomarkers segments in North America which covers markets across the United States, Canada, Mexico and several other regional markets. Companies active in the market are also analyzed and studied in the market research report.

The market for Europe covers smaller market segments of Germany, Italy, France, and the United Kingdom. Additionally, the market research report covers the Asia-Pacific region covering markets from India, China, Japan, Australia, and others. The biomarkers market is also spread across the rest of the world. The market report covers all such regions including the Middle East, Africa, Brazil, and others.

Competitive Landscape:

Biomarkers have seen increased demand over the years, due to the breakthroughs in cardiac biomarkers and immunology biomarkers are predicted to enhance the global biomarkers. Companies functioning in the global biomarkers are also being challenged due to investment required for research and strict regulations. Mergers and acquisitions by biomarkers market companies are anticipated to help the market during the forecast period 2019 to 2027. The report suggests that the market will see a healthy growth in the long run till 2027. Based on SWOT analysis and market’s analysis based on Porters’ Five Force Model presented in the biomarkers market report. Mergers and acquisitions by market companies are anticipated to help the market during the forecast period.

Industry News:

Medidata, a life science technology and clinical trial data firm, reported today that it has acquired the automated biomarker business of sensor manufacturer MC10. The deal's terms were kept under wraps. The acquisition would enable Medidata (a subsidiary of Dassault Systems) to incorporate biometric data and new analytics tools to its Patient Cloud platform, which will support patient-reported results, clinical outcome evaluations, and novel biomarker discovery, according to the company. Meanwhile, large corporations such as Johnson & Johnson and LabCorp have made significant efforts within their divisions to make remote clinical trial designs more feasible.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/biomarker-market-1941

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[morerushikesh]

The Biomarkers Market research report is the study prepared by analysts, which contains a detailed analysis of drivers, restraints, and opportunities along with their impact on the Biomarkers Market growth forecast to 2024.

[bhagyashribhole123]

Global Biomarkers Market 2019: Key companies Profile, their market Share and Growth Insights to 2023

Biomarkers are identifiers of diseases manifested within the body by the body’s natural reaction with the respective disease. The global Biomarkers Market has been mainly driven by the growing medical research sector around the world, including in developed countries such as France, the U.S., and Germany as well as emerging economies such as India, China, and Japan.

The Global Biomarkers Market Size is expected to rise at a CAGR of 13.3% over the forecast period from 2016 to 2022, according to a new report from Market Research Future (MRFR). The report profiles the market’s key drivers and restraints in order to get a clear picture of the market’s progress over the coming years. Major players operating in the global biomarkers market are also assessed in the report to provide readers with a clear understanding of the competitive landscape of the market.

The growing prevalence of communicable diseases as well as chronic noncommunicable diseases, such as cancer, has been vital for the global medical biomarkers market in the last few years. This is likely to remain a key driver for the global biomarker market over the forecast period, as several countries have stepped up their efforts in the medical research sector due to the high profitability of the sector for the players involved in it. The increasing support from regulatory agencies such as the FDA is likely to be crucial for the biomarker market over the forecast period.

The growing prevalence of cancer is likely to be a major driver for the global biomarker market over the forecast period, as biomarkers play a vital role in the early diagnosis of cancer, which allows effective treatment. The growing government expenditure in cancer research is likely to be a major driver for the global biomarker market over the forecast period.

Key Players for Global Biomarkers Market

Merck & Co. Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Enzo Biochem Inc., PerkinElmer Inc., Siemens Healthcare GmbH, and Roche Diagnostics Ltd.

Industry Updates:

In February 2019, researchers at the Indian Institute of Technology in Rourkee identified salivary biomarkers for cancer. This represents a much easier alternative for diagnosis than conventional cancer diagnosis methods.

Segments for Global Biomarkers Market

The Global Biomarkers Market is segmented on the basis of type, indication, application, and region.

The Global Biomarkers Market has been segmented on the basis of type into predisposition biomarkers, diagnostic biomarkers, prognostic biomarkers, and predictive biomarkers.

On the basis of indication, the biomarkers market is segmented into cancer, neurological disorders, cardiovascular disorders, immunological disorders, and others.

On the basis of application, the biomarkers market is segmented into tests, therapies, drug discovery, drug formulation, and others.

Regional Analysis for Global Biomarkers Market

The Global Biomarkers Market is segmented into North America, Europe, Asia Pacific, and the Middle East and Africa on the basis of region.

North America is the dominant regional revenue generator in the global biomarkers market and is likely to remain a leading force over the forecast period, with the regional market expected to grow at a CAGR of 13.6% over the forecast period. The strong presence of several leading players in the biomarkers market is likely to drive the market in North America. The presence of a stable medical research environment is also conducive to steady growth of the biomarkers market in North America over the forecast period. Cancer research is a well-funded endeavor in North America, with government agencies as well as private companies vying to come up with more effective biomarkers for diagnostic purposes. This is likely to be a major driver for the biomarkers market in North America over the forecast period.

Browse More Information:- https://www.marketresearchfuture.com/reports/biomarker-market-1941

Europe holds the second largest regional market share in the global biomarkers market and is likely to exhibit a 13.2% CAGR over the forecast period. The growing medical research sector in Central European countries such as France and Germany is likely to be a major driver for the biomarkers market in the region.

Asia Pacific is likely to exhibit rapid growth over the forecast period in the global biomarkers market due to the growing medical research sector in emerging southeast Asian countries such as India and China. The increasing prevalence of cancer in the region is also likely to drive the biomarkers market in the region over the forecast period.

[super-brandessence1]

Biomarkers Market Size, Share, Trends, Segmentation and Analysis Forecast to 2019 – 2025 | CAGR 14.1%

Biomarkers Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025– Increasing prevalence of cancer and growing precision medicine market are amongst the pivotal factors anticipated to spur the growth of Biomarkers Market.

Biomarkers Market was valued at USD 36.3 Billion in 2018 and expected to reach USD 91.4 Billion by 2025 with a CAGR of 14.1% during the forecast period.

The global biomarkers market is witnessing a healthy growth trajectory attributed to the growing application of biomarkers in diagnostics, increasing funding for biomarkers research, as well as its rising usage in drug discovery. Biomarkers are biological molecules found in body fluids and tissues that help in crucial clinical decision making and diagnosing various health conditions of the patients. Since the molecules can analyze pharmacological responses and pathological indications, they can effectively assist in process of drug discovery and development.

Get Sample Copy of This Premium Report @ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=59521&RequestType=Sample

The diagnostics industry has been witnessing a shift in trend from using conventional diagnostic tools towards using more advanced diagnostic methods that focus on producing accurate and consistent results during early stage of diseases. This has led to boost in demand for biomarkers which are minimally or non-invasive tools to detect diseases such as cancer at early stage. Moreover, growing usage of precision medicine should further boost the biomarkers market growth.

Apart from this, expediting growth in the healthcare IT industry and low costs of clinical trials in emerging countries has favored the entry of various new players in the market. A large chunk of funding is being invested in research and development for new product launches. For instance, in March 2018, Genomic Health, Inc. launched the Oncotype DX AR-V7 Nucleus Detect test. The AR-V7 protein is a prognostic and predictive biomarker. This test aids physicians in taking therapeutic decisions in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs).

Increasing incidence of cancer and growing precision medicine market are some of the pivotal factors boosting the Biomarkers market growth.

Increasing incidence of cancer is one of the pivotal factors which is set to drive the growth of Biomarkers Market. According to World Health Organization (WHO) statistics, various types of cancer accounted for more than 9.5 million deaths in 2018 worldwide. Cancer biomarkers are released by cancer causing tumors that can be detected in blood stream and other tissues, thus helping in early clinical evaluation and deciding the course of treatment.

Moreover, the World Health Assembly has passed the resolution in 2017 for Cancer Prevention and Control. This integrated approach (WHA70.12) has recommended the governments and WHO to speed up action plans specified in the Global Action Plan and 2030 UN Agenda for Sustainable Development to reduce premature mortality from cancer. This has led to a boost in demand for early cancer screening tests and procedures. Increasing focus of research institutes to develop such biomarkers is likely to spur the global Biomarkers Market growth.

North America grabbed the largest share in Biomarkers Market globally

In 2018, North America accounted for the largest share in the global biomarkers market owing to increasing adoption of precision medicine and rising prevalence of cancer in the region. The largest share of the region is also attributed to the rise in number of cancer cases in the U.S. and launch of Precision Medicine Initiative (PMI) by the U.S. government in 2015. According to the National Cancer Institute statistics, more than 16.5 million cases of cancer were diagnosed in 2016 in the U.S, and this number is expected to reach to 19 million in 2024.

The increasing application of biomarkers in the field of precision medicine should also drive the market in this region. Identification of biomarkers is essential for the development of precision medicine. The U.S. precision medicine industry has been booming post the launch of Precision Medicine Initiative by the government in 2015. The initiative aimed at improving the treatment outcome by offering tailor made therapies to patients. This has spurred the development of novel treatments and drugs based on an individual’s genetic profile and characteristics of tumor. The Asia Pacific Biomarkers market is set to showcase lucrative growth in the coming years due to vast patient pool, increasing awareness regarding early disease detection and rising healthcare expenditure in the emerging countries of India and China.  

Recent Developments

In May 2019, Qiagen announced the immediate launch of its first companion diagnostics assay therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) post U.S. FDA regulatory approval as a companion diagnostic to assist in diagnosing breast cancer patients that would be eligible for treatment with newly approved therapy PIQRAY (alpelisib) developed and marketed by Novartis.

Key Players in Biomarkers Market

Some of the major players operating in the Global Biomarkers Market include Siemens Healthineers, Medtronic, F. Hoffman LA Roche Ltd., Abbott Laboratories Nexus-DX, Qiagen N.V., PerkinElmer, Inc., Lifesign LLC., Merck & Co, Inc., Bio-Rad Laboratories, EKF Diagnostics Holdings plc, Singulex, Inc., Signosis, Inc, and BioSims Technologies among others.

Global Biomarkers market is segmented on the basis of product, type, application, and disease indication. The Global Biomarkers Market by product includes consumables, services, and software, while based on type the industry is segmented into safety, efficacy, and validation. By application market segmentation includes diagnostics, drug development, personalized medicine, and disease risk assessment. Biomarkers market by disease indication comprises of cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others.

The geographic analysis in the report spans across North America, Europe, Asia-Pacific and Rest of the World. Further, country level analysis of the Global Anti-Ageing Drugs Market includes U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, and Africa among others.

Get Full information of This Report @ https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Biomarkers-Market-Size/Summary

Biomarkers Market Segmentation: -

By Product:

·         Consumables

·         Services

·         Software

By Type:

·         Safety

·         Efficacy

·         Validation

By Application:

·         Diagnostics

·         Drug Development

·         Personalized Medicine

·         Disease Risk Assessment

By Disease Indication:

·         Cancer

·         Cardiovascular Diseases

·         Neurological Diseases

·         Immunological Diseases

·         Others

By Region & Country:

·         North America

o   U.S.

o   Canada

·         Europe

o   U.K.

o   France

o   Germany

o   Italy

·         Asia Pacific

o   China

o   Japan

o   India

o   Southeast Asia

·         Latin America

o   Brazil

o   Mexico

·         Middle East and Africa

o   GCC

o   Africa

o   Rest of Middle East and Africa

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com

[healthcaremarket242-blog]

Biomarkers Market Business Opportunties and Growth 2018 to 2026

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market.

Biomarker are required for personalized medicine as it helps to identify the unique characteristics of the disease and helps to tailor medicine according to the need of patients. Hence, to cater to demand for personalized medicines, pharmaceutical companies are investing in R&D, which is expected to lead to identification of novel biomarkers, thus aiding in growth of the market.

Request Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

Market Dynamics

The global biomarkers market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel biomarker. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury named Banyan BTI. Such innovations, targeting different indications, is expected to drive biomarkers market growth in the near future.

Key features of the study:

This report provides in-depth analysis of the biomarkers market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies

Moreover, pharmaceutical companies have started outsourcing the complex bio analysis not only to cut down costs, however, to take advantage of specialized expertise to improve efficiency in drug development process. For instance, in March 2018, the SenzaGen signed a key license agreement with Burlesson Research Technologies, Inc., (BRT)—a contract research organization in the U.S., specializing in immunotoxicology. This agreement, will provide BRTs 'GARD' to a broader market. GARD is a group of tests for assessing chemical sensitizers, where the test uses genetic biomarkers for over 200 genes, which cover an entire immune reaction and are relevant to predicting the risk of hypersensitivity. Such advancement and innovation by CROs is expected to favor growth of biomarkers market in the near future.

The biomarkers market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Click To Read More On Biomarkers Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

[expertofmarketinsights-blog]

Biomarkers Market Is Expected To Show Significant Growth Over The Forecast Period 2018-2026

Biomarkers Market Is Expected To Show Significant Growth Over The Forecast Period 2018-2026

The Biomarkers Market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based…

[nerdierthany0u-blog]

Biomarkers Market: Competitive Dynamics & Global Outlook 2026

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market.

Biomarker are required for personalized medicine as it helps to identify the unique characteristics of the disease and helps to tailor medicine according to the need of patients. Hence, to cater to demand for personalized medicines, pharmaceutical companies are investing in R&D, which is expected to lead to identification of novel biomarkers, thus aiding in growth of the market.

Request Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Click To Read More On Biomarkers Market

[ourhealthnewswire-blog]

Biomarkers Market Overview, Demand, Growth, Size, Analysis and Forecast to 2023

A biological marker, commonly known as a biomarker, measures and evaluates biological and pathogenic processes. It also measures pharmacological responses to a therapeutic intervention. Biomarkers are used in predictions, cause, diagnosis, progression, regression and outcome of various diseases. Biomarkers can be specific cell, molecules, genes, gene products, enzymes, hormones, complex organ functions, and general characteristic changes in biological structure.

Explore Request Sample at: https://www.psmarketresearch.com/market-analysis/biomarkers-market/report-sample

High validation cost and high capital requirement for the discovery and development of biomarkers in drug developments are some of the major factors hindering the biomarkers market. Ethical and early diagnosis of the fatal diseases such as cancer and HIV are some major challenge for the biomarker market.

Browse Report at: https://www.psmarketresearch.com/market-analysis/biomarkers-market

Based on the various diseases the global biomarkers market can be segmented as an oncology biomarkers market, cardiology biomarkers market, neurology biomarkers market, other indications biomarkers market, HIV, renal failure, arthritis, tuberculosis, and diabetes.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact: P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook